# short **GUIDE**

## Preterm prelabour rupture of membranes (PPROM)

**IMPORTANT:** Consider individual clinical circumstances. Consult a pharmacopeia for complete drug information. Read the full disclaimer at <a href="www.health.qld.gov.au/qcg">www.health.qld.gov.au/qcg</a>

Aspect	Consideration				
Relevant to:	<ul> <li>Women with a live, singleton fetus with cephalic presentation between 22+0 and 37+0 weeks gestation with suspected preterm prelabour rupture of membranes (PPROM)</li> <li>Sub-categories of preterm variously defined by gestational age as¹:         <ul> <li>Late preterm or near term (34+0 to 37+0 weeks)</li> <li>Moderately preterm (32+0 to 33+6 weeks)</li> <li>Very preterm (28+0 to 31+6 weeks)</li> <li>Extremely preterm (less than 28+0 weeks)</li> </ul> </li> </ul>				
Context	<ul> <li>Occurs in approximately 3% of pregnancies<sup>2,3</sup></li> <li>Responsible for 30% of preterm births<sup>3,4</sup></li> <li>56% of women birth within seven days, 76% within 14 days and 86% within 21 days<sup>2</sup></li> <li>Advise women to present for assessment when PPROM is suspected</li> </ul>				
Standard care	<ul> <li>Refer to Queensland Clinical Guideline: <u>Standard care</u><sup>5</sup> for care considered 'usual' or 'standard'</li> <li>Includes for example: privacy, consent, decision making, sensitive communication, medication administration, staff education and support, culturally appropriate care</li> </ul>				
Aim of care	<ul> <li>Maximise benefits of increasing fetal maturity in-utero while minimising potential risks<sup>4,6</sup></li> <li>Care recommendations are therefore based on gestational age, and individual maternal and fetal circumstances</li> </ul>				
Initial assessment	<ul> <li>Review history and time of fluid loss (sudden gush of fluid or continued leakage of fluid per vagina)</li> <li>Review history (obstetric, social, medical, surgical)</li> <li>Maternal vital signs</li> <li>General physical examination</li> <li>Abdominal palpation (presentation, lie, fundal height, fetal movement and uterine activity)</li> <li>Fetal heart rate (FHR)/cardiotocograph (CTG) (relevant to gestation)</li> <li>Assess vaginal loss on pad (amount, colour, consistency, odour, bleeding, meconium)</li> <li>If unable to confirm PPROM and/or repeat presentation with good history, consider increased surveillance</li> </ul>				
Vaginal examination	<ul> <li>Avoid digital vaginal examination (VE) as may increase risk of infection<sup>3,8</sup></li> <li>Use sterile speculum<sup>3</sup> to visualise<sup>9</sup>:         <ul> <li>Pooling of amniotic fluid or leakage from the cervical os with coughing</li> <li>Cervix, length, dilatation and to exclude cord prolapse</li> </ul> </li> <li>If ongoing uncertainty of diagnosis, test vaginal secretions with immunoassay (e.g. AmniSure®) or pH stick (e.g. Nitrazine) as per manufacturer's instructions</li> <li>False-positive test results may occur in the presence of blood or semen, certain infections (e.g. bacterial vaginosis) or antiseptics<sup>10</sup></li> </ul>				
Investigations	<ul> <li>Routine antenatal bloods that have not already been collected</li> <li>Full blood count</li> <li>Consider baseline C-reactive protein (CRP)         <ul> <li>Conflicting evidence about usefulness in management of PPROM¹¹—may be a useful adjunct to exclude infection (e.g. chorioamnionitis)¹²-¹²</li> </ul> </li> <li>Dipstick urinalysis and midstream urine for microscopy, culture and sensitivity (MCS)         <ul> <li>Consider first void urinary PCR for gonorrhoea and chlamydia</li> </ul> </li> <li>Vaginal-rectal swab or vaginal-perianal swab for Group B Streptococcus (GBS)         <ul> <li>If GBS positive, refer to Queensland Clinical Guideline: Early onset Group B Streptococcal Disease¹¹² for management options</li> </ul> </li> <li>With sterile speculum:         <ul> <li>High vaginal swab for MCS and GBS (if not already obtained)</li> <li>Transabdominal ultrasound scan to assess fetal wellbeing and confirm presentation</li> </ul> </li> </ul>				



Available from: www.health.qld.gov.au/qcg



### **Initial management**

Aspect	Considerations
Admission and inpatient care	<ul> <li>If confirmed PPROM, admit for further assessment and monitoring as per local protocols</li> <li>Maintain a high index of suspicion for:         <ul> <li>Cord prolapse</li> <li>Antepartum haemorrhage</li> <li>Infection—suggested initial monitoring:                 <ul> <li>Four hourly maternal heart rate, temperature, vaginal loss, uterine tenderness/activity, ask about fetal movements, FHR</li> <li>If equal to, or greater than 28+0 weeks gestation, admission and daily CTG</li> </ul> </li> <li>If chorioamnionitis suspected, recommend intravenous (IV) antibiotics—refer to Queensland Clinical Guideline: Preterm labour and birth <sup>19</sup></li> <li>Cerclage removal: optimal timing is unclear<sup>9</sup></li> <li>No significant differences in prolonged latency, infection or neonatal outcomes<sup>20-22</sup> for removal versus retention</li> <li>Delaying removal until 24 to 34 weeks gestation without signs of infection of preterm labour, may be considered to facilitate in-utero transfer, when required<sup>23</sup></li> </ul></li></ul>
Routine antibiotics	<ul> <li>Known to prolong latency and reduce maternal and fetal infection following PPROM<sup>24</sup> <ul> <li>No evidence that antibiotic prophylaxis alters perinatal mortality or longer-term outcomes<sup>25</sup></li> </ul> </li> <li>Optimal regimen is unclear<sup>9,25</sup>—if no local protocols exist recommend<sup>26</sup>:         <ul> <li>Amoxicillin/ampicillin 2 g IV every 6 hours for 48 hours, followed by amoxicillin 250 mg oral every 8 hours for a total of 7 days (IV and oral) or until birth (whichever is sooner)</li> <li>PLUS</li> <li>Erythromycin 250 mg (or erythromycin ethyl succinate 400 mg) oral every 6 hours for 7 days or until birth (whichever is sooner)</li> </ul> </li> <li>Azithromycin 1 g oral as a single dose may be considered in lieu of erythromycin<sup>27,28</sup></li> <li>If history of confirmed penicillin hypersensitivity erythromycin may be used as a single agent for 10 days. <sup>26</sup> Consider referral to an infectious diseases clinician and eTG prophylaxis for PPROM<sup>26</sup></li> <li>Amoxicillin/clavulanic acid not recommended as associated with increased risk of necrotising enterocolitis<sup>9,24</sup></li> </ul>
Prematurity	<ul> <li>Refer to <u>Queensland Clinical Guidelines</u> for recommendations regarding:         <ul> <li>Antenatal corticosteroids<sup>29</sup></li> <li>Magnesium sulfate for neuroprotection (before 30 weeks gestation)<sup>19</sup></li> <li>Care of gestations at the lower limits of viability<sup>30</sup></li> <li>Intrapartum antibiotic prophylaxis for GBS<sup>18</sup></li> </ul> </li> </ul>
Supportive care for families	<ul> <li>Counsel about prematurity relevant to gestation<sup>9</sup> including (if appropriate) viability and options for care</li> <li>Offer psychological support</li> <li>Involve other members of the multidisciplinary team relevant to circumstances in care planning (e.g. neonatologist, paediatrician, social worker, maternal fetal medicine specialist)</li> </ul>
Self-care advice	<ul> <li>Advise about risk of cord prolapse and emergency management if occurs</li> <li>Advise about the risk of infection and the importance of:         <ul> <li>Personal hygiene—change sanitary pad four hourly, showering and not bathing</li> <li>Self-monitoring temperature daily and vaginal loss with each pad change</li> <li>Avoiding tampon use, vaginal creams/medications, vaginal intercourse, swimming/baths</li> <li>Attending all review appointments</li> </ul> </li> <li>Provide information and advise to seek care from a healthcare provider if:         <ul> <li>Concern re fetal movements [refer to Queensland Clinical Guideline: Fetal movements<sup>31</sup>]</li> <li>Changes in vaginal loss (colour, odour, amount, bleeding, or meconium)</li> <li>Signs of early labour/abdominal tenderness or pain</li> <li>Temperature 37.5 °C or above or feeling unwell or other concerns</li> </ul> </li> </ul>
In-utero transfer	<ul> <li>Consider the likelihood of preterm birth and potential need for transfer to higher level service</li> <li>Tocolysis may be considered to achieve antenatal corticosteroid administration or transfer</li> <li>If indicated, contact Retrieval Services Queensland (RSQ) to discuss and coordinate transfer</li> </ul>
Home care	<ul> <li>Consider individual circumstances when determining suitability for home care or other hospital supported accommodation (e.g. on or off hospital campus accommodation)</li> <li>Insufficient evidence to compare planned home versus hospital management for serious neonatal morbidity, chorioamnionitis, gestational age at birth, birth weight, admission to neonatal intensive care<sup>4</sup> or continuous bed rest<sup>28</sup></li> </ul>



#### **Ongoing surveillance**

There is a lack of high level evidence about optimal frequency, or type of ongoing maternal and fetal surveillance. Local protocols may vary. The following *minimum* surveillance is based on the consensus view of the working party. Increase frequency, perform a clinical examination and seek medical review if there is concern for maternal and/or fetal wellbeing.

#### Suggested minimum surveillance

Surveillance	Frequency	Comment				
Maternal self-monitoring						
Temperature and heart rate	Daily to twice daily	Review and record at each presentation				
Vaginal loss	With pad changes	Note any change in colour, odour, amount, meconium, bleeding				
Uterine tenderness/activity	Ongoing	May indicate preterm labour or chorioamnionitis				
Fetal movements	<ul> <li>Note usual pattern and frequency of movement</li> </ul>	<ul> <li>if changes, arrange medical review and CTG</li> </ul>				
Maternal wellbeing	Ongoing	Further investigations as indicated				
Fetal						
CTG/FHR	Weekly and with each presentation	<ul> <li>CTG as per local protocol—if no local protocol CTG if greater than 28–30 weeks</li> <li>Fetal tachycardia may indicate infection<sup>10</sup></li> </ul>				
Ultrasound scan	Serial second weekly as indicated	If greater than 23 weeks—discuss with maternal fetal medicine specialist				
Pathology						
Full blood count	If indicated	<ul> <li>Limited evidence for detection of uterine infection and/or improving maternal and neonatal outcomes<sup>32</sup></li> </ul>				
Urine MCS	If indicated	Refer to investigations				
High/low vaginal swab	If indicated	Refer to investigations				

#### Outcomes for planned birth versus expectant management (24–37 weeks gestation)

Outcomes	Trials	Participants (n=number)	Relative risk	Confidence interval (95%)	Interpretation
Antepartum haemorrhage <sup>33</sup> > 34 weeks	1	n=1835	0.5	0.4 to 0.9	Less likely
Chorioamnionitis <sup>34</sup> > 34 weeks < 34 weeks	3 4	n=847 n=418	0.26 0.77	0.12 to 0.57 0.45 to 1.30	Less likely No significant difference
Caesarean section <sup>34</sup> > 34 weeks < 34 weeks	5 5	n=2922 n=488	1.22 1.46	1.05 to 1.42 1.08 to 1.42	No significant difference No significant difference
Endometritis <sup>34</sup> > 34 weeks < 34 weeks	3 4	n=2562 n=418	0.37 2.23	0.10 to 1.4 1.29 to 3.84	No significant difference Decreased
Neonatal infection <sup>34</sup> > 34 weeks < 34 weeks	12 5	n=3628 n=490	0.93 1.61	0.66 to 1.30 0.74 to 3.50	No significant difference No significant difference
Respiratory distress <sup>33</sup> > 34 weeks	1	n=1829	1.60	1.10 to 2.30	More likely

<sup>&</sup>gt; greater than, < less than





#### Timing of birth

Optimal gestation at which to expedite birth is unclear.<sup>34,35</sup> Individually consider the possibility of expectant management after 24+0 weeks gestation until at least 37+0 weeks gestation.<sup>3</sup>

Aspect	Considerations		
Near term	Between 34+0 and 37+0 weeks there is limited and inconsistent evidence to guide practice		
Less than 34+0 weeks	The risks of prematurity are generally greater than the risks of expectant management		
Consider expediting birth	If concern for maternal or fetal wellbeing at initial presentation or during subsequent care		

#### References

- 1. World Health Organization. Born too soon: decade of action on preterm birth. [Internet]. 2023 [cited 2023 June 27]. Available from: http://www.who.int.
- 2. Feduniw S, Gaca Z, Malinowska O, Brunets W, Zgliczyńska M, Włodarczyk M, et al. The management of pregnancy complicated with the previable preterm and preterm premature rupture of the membranes: What about a limit of neonatal viability? Diagnostics. [Internet]. 2022 [cited 2023 July 3]; 12(8):2025 DOI:10.3390/diagnostics12082025.
- 3. Royal College of Obstetricians and Gynaecologists. Care of women presenting with suspected preterm prelabour rupture of membranes from 24+0 weeks of gestation. Guideline No. Green-top Guideline No. 73. [Internet]. 2019. [cited 2023 July 3]. Available from: <a href="https://rcog.org.uk">https://rcog.org.uk</a>.
- 4. Abou El Senoun G, Dowswell T, HA M. Planned home versus hospital care for pretermprelabour rupture of themembranes (PPROM) prior to 37 weeks' gestation. Cochrane Database of Systematic Reviews. [Internet]. 2014, [cited 2023 August 8]. Issue 4. Art No.: CD008053. DOI:10.1002/14651858.CD008053.pub3.
- 5. Queensland Clinical Guidelines. Standard care. Guideline No. MN22.50-V2-R27. [Internet]. Queensland Health. 2022. [cited 2023 September 1]. Available from: https://www.health.gld.gov.au/gcg.
- 6. White SW, Newnham JP. Is it possible to safely prevent late preterm and early term births? Seminars in Fetal and Neonatal Medicine. [Internet]. 2019 [cited 2023 August 8]; 24(1):33-6 DOI:10.1016/j.siny.2018.10.006.
- 7. Queensland Clinical Guidelines. Normal birth. Guideline No. MN22.25-V4-R27. [Internet]. Queensland Health. 2022. [cited 2023 July 3]. Available from: <a href="https://www.health.qld.gov.au/qcg">https://www.health.qld.gov.au/qcg</a>.
- 8. McElrath T. Prelabor rupture of membranes before and at the limit of viability. 2023. UpToDate Inc. Waltham MA. [cited 2023 July 3]. Available from: https://www.uptodate.com.
- 9. American College of Obstetricians and Gynecologists. ACOG practice bulletin 217: Prelabour rupture of membranes. Obstetrics and Gynecology,. [Internet]. 2020 [cited 2023 August 8]; 135. Available from: <a href="https://www.acog.org/">https://www.acog.org/</a>.
- 10. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Term prelabour rupture of membranes (Term PROM). 2021. [cited 2023 August 8]. Available from: https://ranzcog.edu.au.
- 11. Angela Koech E, Geoffrey O, Abraham Mwaniki M, Marleen T. Maternal inflammatory markers for chorioamnionitis in preterm prelabour rupture of membranes: a systematic review and meta-analysis of diagnostic test accuracy studies. BioMedCentral Systematic Reviews. [Internet]. 2020 [cited 2023 August 8]; 9:1-14 DOI:10.1186/s13643-020-01389-4.
- 12. Musilova I, Andrys C, Krejsek J, Drahosova M, Zednikova B, Pliskova L, et al. Amniotic fluid pentraxins: potential early markers for identifying intra-amniotic inflammatory complications in preterm pre-labor rupture of membranes. American Journal of Reproductive Immunology. [Internet]. 2018 [cited 2023 July 3]; 79(5):e12789-e DOI:10.1111/aji.12789.
- 13. Stepan M, Cobo T, Musilova I, Hornychova H, Jacobsson B, Kacerovsky M. Maternal serum c-reactive protein in women with preterm prelabor rupture of membranes. Public Library of Science. [Internet]. 2016 [cited 2023 July 3]; 11(3):e0150217 DOI:10.1371/journal.pone.0150217.
- 14. Sung J-H, Choi S-J, Oh S-y, Roh C-R, Kim J-H. Revisiting the diagnostic criteria of clinical chorioamnionitis in preterm birth. British Journal of Obstetrics and Gynaecology. [Internet]. 2017 [cited 2023 July 3]; 124(5):775-83 DOI:10.1111/1471-0528.14176.
- 15. Wang Y, Xu Y, Wang S, Wang X, Gu Y, Zhang Y. Prediction of intrauterine inflammation in patients with preterm premature rupture of membranes at 28 to 34 weeks of gestation. Clinical and Experimental Obstetrics & Gynaecology. [Internet]. 2022 [cited 2023 November 8]; 49(2) DOI:10.31083/j.ceog4902042.
- 16. Etyang AK, Omuse G, Mukaindo AM, Temmerman M. Maternal inflammatory markers for chorioamnionitis in preterm prelabour rupture of membranes: a systematic review and meta-analysis of diagnostic test accuracy studies. Systematic Reviews. [Internet]. 2020 [cited 2023 November 8]; 9(1):141 DOI:10.1186/s13643-020-01389-4.
- 17. Thomson AJ. Care of Women Presenting with Suspected Preterm Prelabour Rupture of Membranes from 24(+0) Weeks of Gestation: Green-top Guideline No. 73. British Journal of Obstetrics and Gynaecology. [Internet]. 2019 [cited 2023 November 8]; 126(9):e152-e66 DOI:10.1111/1471-0528.15803.

(CC) BY-NC-ND



- 18. Queensland Clinical Guidelines. Early onset Group B Streptococcal disease. Guideline No. MN22.20-V6-R27. [Internet]. Queensland Health. 2022. [cited 2023 July 3]. Available from: https://www.health.gld.gov.au/gcg.
- 19. Queensland Clinical Guidelines. Preterm labour and birth Guideline No. MN20.6-V10-R25. [Internet]. Queensland Health. 2020. [cited 2023 July 3]. Available from: <a href="https://www.health.qld.gov.au/qcg">https://www.health.qld.gov.au/qcg</a>.
- 20. Galyean A, Garite TJ, Maurel K, Abril D, Adair CD, Browne P, et al. Removal versus retention of cerclage in preterm premature rupture of membranes: a randomized controlled trial. American Journal of Obstetrics and Gynecology. [Internet]. 2014 [cited 2023 August 8]; 211(4):399.e1-7 DOI:10.1016/j.ajog.2014.04.009.
- 21. Laskin MD, Yinon Y, WL. W. Preterm premature rupture of membranes in the presence of cerclage: is the risk for intra-uterine infection and adverse neonatal outcome increased? Journal of Maternal Fetal Neonatal Medicine. [Internet]. 2012 [cited 2023 August 8]; 25(4):424-8 DOI:10.3109/14767058.2011.569800
- 22. Vitner D, Melamed N, Elhadad D, Phang M, Ram M, Asztalos E, et al. Removal vs. retention of cervical cerclage in pregnancies complicated by preterm premature rupture of membranes: a retrospective study. Archives of Gynecology and Obstetrics. [Internet]. 2020 [cited 2023 August 8]; 302(3):603-9 DOI:10.1007/s00404-020-05642-y.
- 23. Royal College of Obstetricians and Gynaecologists. Cervical Cerclage. Guideline No. Green-top guideline no. 75. [Internet]. 2022. [cited 2023 August 8]. Available from: <a href="https://rcog.org.uk">https://rcog.org.uk</a>.
- 24. Kenyon S, Boulvain M, JP N. Antibiotics for preterm rupture of membranes. Cochrane Database of Systematic Reviews. [Internet]. 2013, [cited 2023 August 8]. Issue 12. Art No.: CD001058. DOI:10.1002/14651858.CD001058.pub3.
- 25. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Prophylactic antibiotics in obstetrics and gynaecology. C-Gen 17. [Internet]. 2021. [cited 2023 August 8]. Available from: <a href="https://ranzcog.edu.au">https://ranzcog.edu.au</a>.
- 26. Therapeutic Guidelines. Prophylaxis for preterm prelabour rupture of membranes. [Internet]. 2021 [cited 2023 August 8]. Available from: <a href="https://tgldcdp.tg.org.au/">https://tgldcdp.tg.org.au/</a>.
- 27. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Prophylactic antibiotics in obstetrics and gynaecology. Best practice statement. [Internet]. 2021. [cited 2023 September 1]. Available from: <a href="https://ranzcog.edu.au">https://ranzcog.edu.au</a>.
- 28. Ronzoni S, Boucoiran I, Yudin MH, Coolen J, Pylypjuk C, Melamed N, et al. Guideline No. 430: Diagnosis and management of preterm prelabour rupture of membranes. Journal of Obstetrics and Gynaecology Canada. [Internet]. 2022 [cited 2023 August 30]; 44(11):1193-208.e1 DOI:10.1016/j.jogc.2022.08.014.
- 29. Queensland Clinical Guidelines. Antenatal corticosteroids. Guideline No. MN21.64-V1-R26. [Internet]. Queensland Health. 2021. [cited 2023 August 8]. Available from: https://www.health.gld.gov.au/qcg.
- 30. Queensland Clinical Guidelines. Perinatal care of the extremely preterm baby. Guideline No. MN20.32-V2-R25. [Internet]. Queensland Health. 2020. [cited 2023 August 8]. Available from: https://www.health.gld.gov.au/gcg.
- 31. Queensland Clinical Guidelines. Fetal movements. Guideline No. MN23.46-V2-R28. [Internet]. Queensland Health. 2023. [cited 2023 August 8]. Available from: https://www.health.qld.gov.au/qcg.
- 32. Tita TN, Andrews WW. Diagnosis and management of clinical chorioamnionitis. Clinical Perinatology. [Internet]. 2010 [cited 2023 August 9]; 37(2):339-54 DOI:10.1016/j.clp.2010.02.003.
- 33. Morris JM, Roberts CL, Bowen JR, Patterson JA, Bond DM, Algert CS, et al. Immediate delivery compared with expectant management after preterm pre-labour rupture of the membranes close to term (PPROMT trial): a randomised controlled trial. Lancet. [Internet]. 2016 [cited 2023 August 9]; 387(10017):444-52 DOI:10.1016/S0140-6736(15)00724-2.
- 34. Bond D, Middleton P, Levett K, van der Ham D, Crowther C, Buchanan S, et al. Planned early birth versus expectant management for women with preterm prelabour rupture of membranes prior to 37 weeks' gestation for improving pregnancy outcome. Cochrane Database of Systematic Reviews. [Internet]. 2017, [cited 2023 August 8]. Issue 3. Art No.: CD004735. DOI:10.1002/14651858.CD004735.pub4.
- 35. Quist-Nelson J, de Ruigh AA, Seidler AL, van der Ham DP, Willekes C, Berghella V, et al. Immediate delivery compared with expectant management in late preterm prelabor rupture of membranes: an individual participant data meta-analysis. Obstetrics and Gynecology,. [Internet]. 2018 [cited 2023 August 9]; 131(2):269-79 DOI:10.1097/AOG.000000000002447.